Eledon Pharmaceuticals Publishes Presentation on Patient-Reported Outcomes in Phase 2 BESTOW Trial

Bitget2026/10/26 12:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eledon Pharmaceuticals published its ASN Kidney Week 2026 presentation on patient-reported outcomes from the Phase 2 BESTOW kidney transplant trial.
Tegoprubart improved all five quality-of-life subscales through Month 12, compared with four of five for tacrolimus.
Symptoms and problems scores improved 9.0 points with tegoprubart versus 3.3 with tacrolimus, a statistically significant difference (p < 0.05).
Month 12 symptom occurrence scores were significantly lower with tegoprubart at 18.6 versus 25.7 with tacrolimus.
Kidney function was higher with tegoprubart across all measurable time points; biopsy-proven acute rejection did not differ between groups at Month 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03

Nvidia continues to plummet, losing $430 billion in market value over two days, with Microsoft temporarily reclaiming the world's second place.

On Tuesday, Nvidia closed down 5.5%, a decline significantly greater than other major tech stocks, making it a key factor dragging down the tech sector's performance. During intraday trading on Tuesday, Microsoft's market capitalization briefly surpassed Nvidia, making it the world's second largest publicly traded company by market value. However, after Anthropic released its office suite, Microsoft's losses widened, causing it to fall behind Nvidia once again.

华尔街见闻•2026/11/10 23:01